| abstract |
The present disclosure relates to combination therapies with antibody conjugates with binding specificity for folate receptor alpha (FOLR1) and its isoforms and homologs, and compositions comprising combinations with the antibody conjugates, including pharmaceutical compositions. Also provided are methods of using the combinations with antibody conjugates and compositions thereof, such as in therapeutic and diagnostic methods. |